Questions across 84 calls

Tushar Manudhane

Motilal Oswal Financial Services

Global Health Limited

Global Health Limited CC-Mar24.pdf · 2024-05-20

Sir, just on capex, if you could share for this year, FY25 and FY26, which projects and what quantum of capex will be incurring? I guess because Noida is largely done, DLF might take some time. So, if you could share some thoughts on capex first?

Got it, sir. And secondly, sir, given that directionally now that almost 98 beds already added in Lucknow, another 47 beds to be added in Q1, FY25. So, directionally, we will have some increase in operational cost or the current fourt h quarter number already reflects the additional cost on because of these beds?

Global Health Limited CC-Sep23.pdf · 2023-11-10

Thanks for the opportunity. Congratulations on good set of numbers and happy Diwali to the entire team. Sir, my question refers to more on the Patna. If you could share some ballpark profitability for Patna Hospital now?

The profitability of the margin side Patna for first half FY ‘24 or 2Q FY ’24?

Mankind Pharma Limited

Mankind Pharma Limited CC-Mar24.pdf · 2024-05-16

Sir, just on the respiratory division, which was launched in 2021. So currently, how many MRs would be there, and it's heartening to know that we've got this Symbicort in the portfolio. So if you could just elaborate in terms of number of MRs? And what kind of deal does Astra Zeneca have with us?

Got you. But even on the size wise, at least as far as the therapeutic composition is given in the presentation, respiratory is 5% of domestic business, which comes to almost about INR500 crores, right? So is that the right way to understand respiratory?

Piramal Pharma Limited

Piramal Pharma Limited CC-Mar24.pdf · 2024-05-13

Just on the CDMO side, there has been a good scale-up this year and even for that matter in 4Q FY’24 with 18% growth, considering the order book, considering the biotech funding for example, like how do you see this growth momentum for '25-'26, 5 -year given early teens growth, does it mean that you will have a much better growth in CDMO, but that would be partly offset by certain issues in CHG segment?

And if you further elaborate in terms of whether you will have more number of molecules getting into the commercial side, the Phase-3 trials further getting into commercial side, is that is what is driving growth or it is more number of projects across clinical trials that would drive the growth?

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited CC-Mar24.pdf · 2024-05-07

So on Rituximab, just trying to understand the progress as far as the Europe filing is concerned?

Understood. Secondly, on the inventory , I s ee quarter-on-quarter reasonable increase, if you could explain that?

Dr. Reddy's Laboratories Limited CC-Dec23.pdf · 2024-01-30

Ya, thanks for the opportunity. Sir, firstly, on the receivables which have increased on a quarter- on-quarter basis - is this on certain select products or is it across the portfolio ? And for which markets?

Ok. Secondly, gross margin for PSAI segment has been higher for the quarter , compared to the previous quarters. So, anything in specific you'd like to comment?

Dr. Reddy's Laboratories Limited CC-Sep23.pdf · 2023-10-27

Just on this e-commerce foray, so would like to understand what is the strategy behind it, what kind of investment are we thinking in this particular foray?

But in addition to the typical nutraceutical products, would we be also having this prescription- based product on this platform?

Ajanta Pharma Limited

Ajanta Pharma Limited CC-Mar24.pdf · 2024-05-02

Sir, on the India business at the industry level, the growth seems to be significantly on the downtrend. If you could share your experience in terms of the outlook, not just for FY'25, but maybe next 2, 3 years, how to think about the industry growth prospects?

And then secondly, on Asia market, the last 2 quarters, we have seen the phenomenal offtake at an absolute sales level from almost Rs. 230 crores, Rs. 240 crores average quarterly run rate , now we are at Rs. 280 crores, Rs. 290 crores. So if you could shed some more light over here and specifically Asia market, how to think about for next couple of years.

Ajanta Pharma Limited CC-Dec23.pdf · 2024-01-31

Sir, just on the India business clarification, what kind of growth we can anticipate for FY '24, given that Q3 FY '24 was a bit softer?

I was actually referring for FY '24 that we have grown by 10 -11% for 9 months and we are talking about 12-13% for full year of '24. So, does it mean that we will grow at a healthy rate of 13-15% for Q4?

Ajanta Pharma Limited CC-Sep23.pdf · 2023-10-31

So, just on the capacity utilization currently at different plants?

So, effectively, that would trigger more CAPEX maybe in the next 12 to 15 months?

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2024-04-25

So, firstly, on this $40 million fermentation CAPEX, so is this considering the contract already in hand or you are building the facility and then subsequently we will look for the contract?

And sir, out of this total Rs. 700 crore CAPEX which we have envisaged for FY25, how much would be funded from internal accruals, or will there be further increase in debt?

Laurus Labs Limited CC-Mar24.pdf · 2024-04-25

So, firstly, on this $40 million fermentation CAPEX, so is this considering the contract already in hand or you are building the facility and then subsequently we will look for the contract?

And sir, out of this total Rs. 700 crore CAPEX which we have envisaged for FY25, how much would be funded from internal accruals, or will there be further increase in debt?

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited CC-Dec23.pdf · 2024-02-16

Sir, just a clarification on the R&D spend, particularly for 4Q FY '24. And then you had already highlighted about FY '25 R&D spend going down by $30 million, $35 million. But let's say, for 4Q, how much do we consider?

Glenmark Pharmaceuticals Limited CC-Sep23.pdf · 2023-11-15

So, the first is on the bookkeeping part. Rs.325 crores is an exceptional loss. Even if I exclude 30 million from that settlement payment, still the remaining amount is considerable. Is it largely to do with remediation measures?

Derma is a therapy in India has witnessed good slowdown. So, any particular reasons to highlight here?

Divi's Laboratories Limited

Divi's Laboratories Limited CC-Dec23.pdf · 2024-02-10

The GLP-1 protected amino acids where you are under qualification with various customers, would this require subsequent CAPEX and then the commercial benefit or we already have the capacity to gain the traction post-approval?

And typically, this would be what as a percentage of API cost of this GLP-1, the protected amino acids?

Divi's Laboratories Limited CC-Sep23.pdf · 2023-11-06

Sir, just on -- firstly, on this inventory write-off of INR20 crores, so how different is this from a typical over past many quarters?

Understood. And secondly, with respect to Unit 3, where the construction is currently ongoing, but the production is expected to commence from first quarter FY '25, so what kind of operational cost one should build in?

Cipla Limited

Cipla Limited CC-Dec23.pdf · 2024-01-25

Just clarity on Abraxane, if you could just highlight any particular reason for delay -- rechange in the plan as far as filing for the alternate site is concerned? And secondly, if it is so, then it would be again subject to the reinspection of Goa facilities. So accordingly, is there a change in timeline as far as the approval is concerned for Abraxane?

And -- but now then the reinspection of Goa and then subsequently the approval so likewise, any change in the timeline for approval for Abraxane?

Cipla Limited CC-Sep23.pdf · 2023-10-27

Just with respect to the product which you have highlighted to be launched in FY24 the peptide product, if you could share some market size competitive scenario for other products?

The market size at least?

Granules India Limited

Granules India Limited CC-Dec23.pdf · 2024-01-23

Sir, just on this DCDA, now that plant is expected to start in Q4 FY24, so effectively stabilization and then meaningful contribution to profitability when should we start expecting?

This is to do with DCDA, right? Not the FDA?

Max Healthcare Institute Limited

Max Healthcare Institute Limited CC-Sep23.pdf · 2023-11-07

So, just on the organic basis, on EBITDA per bed, while we've already, I presume you've optimized in terms of efficiency at the overall level. So, how do you think about the levers for improving EBITDA per bed for the next two to three years?

Right. Okay.